Shares in US pharma Vertex were up sharply in premarket trading after its newly-launched cystic fibrosis triple therapy attained blockbuster status almost overnight, leading
As the global COVID-19 outbreak continues to tighten its grip, people with underlying respiratory conditions such as cystic fibrosis (CF) are particularly vulnerable.
